Here we report the results of the phase 1/2 umbrella trial NCT Neuro Master Match (N<sup>2</sup>M<sup>2</sup>), which evaluated targeted treatments in 228 patients with newly diagnosed glioblastoma without O6-methylguanine DNA-methyltransferase promoter hypermethylation. The gene discussed is MGMT; the disease is glioblastoma.